TY  -  
T1  - Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer : Quo Vadis? 
SN  -  /  
UR  - http://hdl.handle.net/10138/326843 
T3  -  
A1  - Boussios, Stergios; Moschetta, Michele; Karihtala, Peeter; Samartzis, Eleftherios P.; Sheriff, Matin; Pappas-Gogos, George; Ozturk, Mehmet Akif; Uccello, Mario; Karathanasi, Afroditi; Tringos, Michail; Rassy, Elie; Pavlidis, Nicholas 
A2  -  
PB  -  
Y1  - 2020 
LA  - eng 
AB  - Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality among women, potentially due to ineffectiveness of screening tests for early detection. Patients typically present with advanced disease at diagnosis, whereas, up to 80% relapse and the estimated median progression-free survival (PFS) is approximately 12-18 months. Increased knowledge on the molecular biology of EOC resulted in the development of several targeted therapies, including poly(ADP-ribose) polymerase (PARP)... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - Ovarian cancer; breast cancer gene (BRCA); poly(ADP-ribose) polymerase inhibitors (PARP inhibitors); homologous recombination (HR); veliparib; talazoparib; OLAPARIB MAINTENANCE THERAPY; ABDOMINAL RADIATION-THERAPY; ADVANCED SOLID MALIGNANCIES; PHASE-I; FALLOPIAN-TUBE; PRIMARY PERITONEAL; VELIPARIB ABT-888; DOSE-ESCALATION; EPITHELIAL OVARIAN; JAPANESE PATIENTS; 3122 Cancers 
N1  -   
PP  -  
ER  -